학술논문
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Document Type
Article
Author
Saad, Fred ; Clarke, Noel W ; Oya, Mototsugu; Shore, Neal; Procopio, Giuseppe; Guedes, João Daniel; Arslan, Cagatay; Mehra, Niven; Parnis, Francis; Brown, Emma; Schlürmann, Friederike; Joung, Jae Young; Sugimoto, Mikio; Sartor, Oliver; Liu, Yu-Zhen; Poehlein, Christian; Barker, Laura; del Rosario, Paula Michelle; Armstrong, Andrew J
Source
In The Lancet Oncology October 2023 24(10):1094-1108
Subject
Language
ISSN
1470-2045